0 results available. Select is focused ,type to refine list, press Down to open the menu,
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous...
The following section summarizes insights on Cytosorbents Crp's P/E Ratio:
We've identified the following companies as similar to Cytosorbents Crp because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to P/E Ratio in the valuation category include:
Indicates the multiple of earnings that stock investors are willing to pay for one share of the firm.
Price-to-Earnings ratio, P/E Multiple, or P/E Ratio is valuation multiple that is defined as:
P/E Ratio = Market Capitalization / Net Income
or, using per-share numbers:
P/E Ratio = Stock Price / Earnings Per Share (EPS)
Applying this formula, Cytosorbents’s P/E Ratio is calculated below:
Market Capitalization [ 54.351 M ]
(/) Net Income [ -20.719 M ]
(=) P/E Ratio [ −2.6x ]
P/E Ratio indicates the multiple of earnings investors are willing to pay for one share of the company. PE Multiples are widely used in practice even though they have significant pitfalls.
Since Earnings Per Share (EPS), defined as Net Income / Shares Outstanding, uses a Net Income in the calculation, P/E multiples are not always reliable for benchmarking companies with negative earnings or debt.
One reason why P/E ratios can be unreliable is because the ratio assumes a company’s equity has value. In practice, a company’s total Firm Value may be less than the debt on its Balance Sheet, with no value allocatable to the common equity. P/E ratios also do not adjust for differences in capital structure between companies. P/E conundrum by Khan Academy does a great job of explaining these pitfalls.
The tables below summarizes the trend in Cytosorbents’s p/e ratio over the last five years:
| Date | Market Cap | Earnings | P/E Ratio |
|---|---|---|---|
| 2020-12-31 | 344.1 M | −11.1 | −31.0 |
| 2021-12-31 | 182.2 M | −15.9 | −11.4 |
| 2022-12-31 | 67.635 M | −41.4 | −1.6 |
| 2023-12-31 | 57.955 M | −23.4 | −2.5 |
| 2024-12-31 | 49.758 M | −19.0 | −2.6 |
Read more about net income to common excl extra items and market cap
The chart above depicts the distribution of p/e ratio for companies operating in the Healthcare sector in the Developed economic region. Over 2,450 companies were considered in this analysis, and 2,355 had meaningful values. The average p/e ratio of companies in the sector is 1.4x with a standard deviation of 20.9x.
Cytosorbents Crp's P/E Ratio of -2.6x ranks in the 37.4% percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 2,453 |
| Included Constituents | 2,355 |
| Min | -100.3x |
| Max | 133.4x |
| Median | -1.2x |
| Mean | 1.4x |
| Standard Deviation | 20.9x |
You can find companies with similar p/e ratio using this stock screener.